Manage your formulary budget
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Find generic entry opportunities
Anticipate generic drug launch
Proactively manage your pharmacy inventory
Drug patents …
… from Kazakhstan to Kalamazoo
|Title:||Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dih ydro-2H-indol-2-one-hydrochloride|
|Abstract:||The monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydr o-2H-indole-2-one hydrochloride has advantageous stability for formulation as a neuroleptic agent.|
|Inventor(s):||Allen; Douglas J. M. (New London, CT), Busch; Frank R. (Gales Ferry, CT), DiRoma; Sabeto A. (Uncasville, CT), Godek; Dennis M. (Glastonbury, CT)|
|Assignee:||Pfizer Inc. (New York, NY)|
Patent Claim Types:|
see list of patent claims
|Compound; Use; Composition; Process;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.